References

arthyper

Артериальная гипертензия

"Arterial’naya Gipertenziya" ("Arterial Hypertension")

1607-419X2411-8524

Antihypertensive League

10.18705/1607-419X-2012-18-5-375-384

arthyper-1720

Research Article

ОБЗОР

REVIEW

Антигипертензивная терапия антагонистами рецепторов ангиотензина II и риск развития злокачественных новообразований

Antihypertensive therapy with angiotensin II receptor blockers and risk of cancer

Баранова

Е. И.

Baranova

E. I.

eibaranova@yahoo.com

ГБОУ ВПО «Санкт-Петербургский государственный медицинский университет им. акад. И.П. Павлова» Минздравсоцразвития РФРоссияPavlov St Petersburg State Medical UniversityRussian Federation

2012

28102012

185375384

2012

Баранова Е.И.

Baranova E.I.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://htn.almazovcentre.ru/jour/article/view/1720

Обзор литературы посвящен проблеме риска развития злокачественных новообразований на фоне антигипертензивной терапии антагонистами рецепторов ангиотензина II. Содержит данные рандомизированных исследований, обсервационных исследований и крупнейших метаанализов, посвященных этой проблеме.

The article reviews available up-to-date knowledge from randomized trials, observational trials and metaanalyses about the problem of risk of cancer as a possible complication of angiotensin II receptor blockers therapy.

антагонисты рецепторов ангиотензина IIартериальная гипертензиянежелательные явлениязлокачественные новообразования

angiotensin II receptor blockersarterial hypertensionadverse effectrisk of cancer

References1

Шальнова С.А., Кукушкин С., Маношкина Е., Тимофеева Т. Артериальная гипертензия и приверженность терапии // Врач. — 2009. — № 12. — С. 39-42.

Данные Федеральной службы государственной статистики РФ на 11.02.2011. — [Электронный ресурс]. — URL: www.gks.ru / The data of Federal Service of State Statistics of Russian Federation on 11.02.2011. — [Electronic resource]. — URL: www.gks.ru.

Stocks T., Van Hemelrijck M., Manjer J. et al. Blood pressure and risk of cancer incidence and mortality in the metabolic syndrome and cancer project // Hypertension. — 2012. — Vol. 59, № 4. — Р. 802-810.

Volpe M., Tocci G., Pagannone E. Fewer mega-trials and more clinically oriented studies in hypertension research& the case of blocking the rennin-angiotensin-aldosterone system // J. Am. Soc. Nephrol. — 2006. — Vol. 17, № 4, Suppl. 2. — P. S36-S43.

Mancia G., De Backer G., Dominiczak A. et al. 2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension // J. Hypertens. — 2007. — Vol. 25, № 9. — Р. 1751-1762.

Volpe M., Azizi M., Danser A.H. et al. Twisting arms to angiotensin receptor blockers/antagonists: the turn of cancer // Eur. Heart J. — 2011. — Vol. 32, № 1. — Р. 19-22.

Pfeffer M.A., Swedberg K., Granger C.B. et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme // Lancet. — 2003. — Vol. 362, № 9386. — P. 759-766.

Sipahi I., Debanne S.M., Rowland D.Y., Simon D.I., Fang J.C. Angiotensin-receptor blockade and the risk of cancer: meta-analysis of randomized controlled trials // Lancet Oncol. — 2010. — Vol. 11, № 7. — P. 627-636.

Julius S., Kjeldsen S.E., Weber M. et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial // Lancet. — 2004. — Vol. 363, № 9426. — Р. 2022-2031.

Анализ влияния лечения сартанами на риск развития онкологических заболеваний. Информационное письмо Российского медицинского общества по артериальной гипертонии (РМОАГ) // Системные гипертензии. — 2010. — № 4. — С. 77.

Walther T., Menrad A., Orzechowski H.D., Siemeister G., Paul M., Schirner M. Differential regulation of in vivo angiogen-esis by angiotensin II receptors // FASEB J. — 2003. — Vol. 17, № 14. — P. 2061-2067.

Greene A.S., Asmar S.L. Microvascular angiogenesis and the renin-angiotensin system // Curr. Hypertens. Rep. — 2002. — Vol. 4. — P. 56-62.

Sadoshima J., Izumo S. Signal transduction pathways of angiotensin-II-induced c-fos gene expression in cardiac myocytes in vitro. Roles of phospholipid-derived second messengers // Circ. Res. — 1993. — Vol. 73, № 3. — P. 424-438.

Pickel I., Matsuzuka T., Doi C. et al. Overexpression of angiotensinII type 2 receptor gene induces cell death in lung adenocarcinoma cell // Cancer Biol. Ther. — 2010. — Vol. 9, № 4. — [Electronic resource]. — URL: http://www.ncbi.nlm.nih. gov/pmc/articles/PMC2974059/.

Moltzer E., Verkuil A.V., van Veghel R. et al. Effects of angiotensin metabolites in the coronary vascular bed of the spontaneously hypertensive rat: loss of angiotensin II type 2 receptor-mediated vasodilation // Hypertension. — 2010. — Vol. 55, № 2. — Р. 516-522.

Volpe M., Morganti A. on behalf of Executive Committee of the Italian Society of Hypertension (SIIA) 2010 Position Paper of the Italian Society of Hypertension (SIIA). Angiotensin receptor blockers and risk of cancer // High Blood Press. Cardiovasc. Prev. — 2011. — Vol. 18, № 1. — Р. 37-40.

Gong Q., Davis M., Chipitsyna G., Yeo C.J., Arafat H.A. Blocking angiotensin II type 1 receptor triggers apoptotic cell death in human pancreatic cancer cells // Pancreas. — 2010. — Vol. 39, № 5. — P. 581-594.

Munzenmaier D.H., Greene A.S. Opposing actions of angiotensin II on microvascular growth and arterial blood pressure // Hypertension. — 1996. — Vol. 27, № 3, Pt. 2. — P. 760-765.

Coleman C.I., Baker W.L., Kluger J., White C.M. Antihypertension medication and their impact on cancer incidence: a mixed treatment comparison meta-analysis of randomized controlled trials // J. Hypertens. — 2008. — Vol. 26, № 4. — P. 622-629.

Bangalore S., Kumar S., Kjeldsen S.E. et al. Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324,168 participants from randomized trials // Lancet Oncol. — 2011. — Vol. 12, № 1. — P. 65-82.

ARB Trialists Collaboration. Effects of telmisartan, irbe-sartan, valsartan, candesartan, and losartanon cancers in 15 trials enrolling 138,769 individuals // J. Hypertens. — 2011. — Vol. 29, № 4. — P. 623-635.

Lever A.F., Hole D.J., Gillis C.R. et al. Do inhibitors of angiotensin-I-covering enzyme protect against risk of cancer? // Lancet. — 1998. — Vol. 352, № 9123. — Р. 179-184.

Les L. ACE inhibitors may reduce esophageal cancer incidence // Gastroenterology. — 2006. — Vol. 131, № 2. — Р. 343-344.

Opelz G., Dohler B. Treatment of kidney transplant recipients with ACE inhibitor/ARB and risk of respiratory tract cancer: a collaborative transplant study report // Am. J. Transplant. — 2011. — Vol. 11, № 11. — Р. 2483-2489.

Pasternak B., Svanstrom H., Callreus T., Melbye M., Hviid A. Use of angiotensin receptor blockers and risk of cancer // Circulation. — 2011. — Vol. 123, № 16. — P. 1729-1736.

Huang C.C., Chan W.L., Chen Y.C. et al. Angiotensin II receptor blockers and risk of cancer in patients with systemic hypertension // Am. J. Cardiol. — 2011. — Vol. 107, № 7. — P. 1028-1033.

Bhaskaran K., Douglas I., Evans S., van Staa T., Smeeth L. Angiotensin receptor blockers and risk of cancer // Br. Med. J. — 2012. — Vol. 344. — P. e2697. — [Electronic resource]. — URL: http://www.medscape.com/viewarticle/762953.

Herrett E., Thomas S.L., Schoonen W.M., Smeeth L., Hall A.J. Validation and validity of diagnoses in the General Practice Research Database: a systematic review // Br. J. Clin. Pharmacol. — 2010. — Vol. 69, № 1. — P. 4-14.

Wilop S., von Hobe S., Crysandt M. et al. Impact of angiotensin I converting enzyme inhibitors and angiotensin II type 1 receptor blockers on survival in patients with advanced non-small-cell lung cancer undergoing first-line platinum-based chemotherapy // J. Cancer Res. Clin. Oncol. — 2009. — Vol. 135, № 10. — Р. 1429-1435.

Heinzerling J.H., Anthony T., Livingston E.H. et al. Predictors of distant metastasis and mortality in patients with stage II colorectal cancer // Am. Surg. — 2007. — Vol. 73, № 3. — Р. 230-238.

Egami K., Murohara T., Shimada T. et al. Role of host angiotensin II type 1 receptor in tumor angiogenesis and growth // J. Clin. Invest. — 2003. — Vol. 112, № 1. — Р. 67-75.

Fujita M., Hayashi I., Yamashina S. et al. Angiotensin type 1a receptor signaling-dependent induction of vascular endothelial growth factor in stroma is relevant to tumor-associated angiogenesis and tumor growth // Carcinogenesis. — 2005. — Vol. 26, № 2. — Р. 271-279.

Lithell H., Hansson L., Skoog I. et al. The study on cognition and prognosis in the elderly (SCOPE): principal results of a randomized double-blind intervention trial // J. Hypertens. — 2003. — Vol. 21, № 5. — P. 875-886.

FDA Drug Safety Communication: No increase in risk of cancer with certain blood pressure drugs — angiotensin receptor blockers (ARBs). — 2011. — [Electronic resource]. — URL: http:// www.fda.gov/Drugs/DrugSafety/ucm257516.htm.

Stiles S., Barclay L. No cancer risk elevation from ARBs: two new analyses 04/19/2011. — [Electronic resource]. — URL: http://www.medscape.org/viewarticle/741085.

European Medicine Agency concludes that benefit-risk balance of angiotensin II receptor antagonists remains positive. — [Electronic resource]. — URL: http://www.emea.20 OCT 2011 EMA/CHMP/834168/2011.

The authors declare that there are no conflicts of interest present.